Q2 2025 · 13F-HR
Fairmount Funds Management LLCholdings as filed
Filed 2025-08-14 · accession 0001104659-25-078521
$771.9M
Reported value
17
Positions
2025-06-30
Period end
The Brief · Fairmount Funds Management LLC · Q2 2025
AI · grounded in 13F
Fairmount Funds Management LLC established a new position in APGE valued at $88.97M. The fund also initiated new stakes in AXSM for $85.10M and ELVN for $74.45M. These moves contributed to a total AUM of $771.90M across 17 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $89.0M | 11.5% | 2,048,647 | Common | SOLE |
| 05464T104 | AXSM | AXSOME THERAPEUTICS INC | $85.1M | 11.0% | 815,176 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $74.5M | 9.65% | 3,711,444 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $64.6M | 8.37% | 1,824,031 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $60.2M | 7.79% | 4,018,101 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $55.5M | 7.19% | 727,563 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $50.4M | 6.53% | 2,707,191 | Common | SOLE |
| G52694109 | KNSA | KINIKSA PHARMACEUTICALS INTL | $49.1M | 6.36% | 1,772,839 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $48.4M | 6.27% | 3,459,913 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $44.7M | 5.79% | 6,225,641 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $37.8M | 4.90% | 3,371,922 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $32.2M | 4.17% | 3,220,368 | Common | SOLE |
| G2545C104 | CBIO | CRESCENT BIOPHARMA INC. | $22.4M | 2.90% | 1,387,866 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $19.1M | 2.47% | 3,554,129 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $18.3M | 2.38% | 1,892,806 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $11.9M | 1.55% | 6,125,000 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $8.8M | 1.15% | 3,896,582 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.